HRP20220674T1 - Zajednička primjena alfa-amino estera derivata hidroksipropiltiazolidin karboksamida i tokolitičkog sredstva - Google Patents

Zajednička primjena alfa-amino estera derivata hidroksipropiltiazolidin karboksamida i tokolitičkog sredstva Download PDF

Info

Publication number
HRP20220674T1
HRP20220674T1 HRP20220674TT HRP20220674T HRP20220674T1 HR P20220674 T1 HRP20220674 T1 HR P20220674T1 HR P20220674T T HRP20220674T T HR P20220674TT HR P20220674 T HRP20220674 T HR P20220674T HR P20220674 T1 HRP20220674 T1 HR P20220674T1
Authority
HR
Croatia
Prior art keywords
compound
use according
patient
ppm
tocolytic agent
Prior art date
Application number
HRP20220674TT
Other languages
English (en)
Inventor
Patrick NAXOS PAGE
Matthias Schwarz
Catherine Jorand-Lebrun
Anna Quattropani
Vincent Pomel
Ernest Loumaye
Oliver Pohl
Jean-Pierre Gotteland
Original Assignee
ObsEva S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/987,586 external-priority patent/US9447055B1/en
Application filed by ObsEva S.A. filed Critical ObsEva S.A.
Publication of HRP20220674T1 publication Critical patent/HRP20220674T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Emergency Medicine (AREA)

Claims (18)

1. Spoj, naznačen time, da je predstavljen formulom (I) [image] ili njegova farmaceutski prihvatljiva sol, koji je za uporabu u liječenju ili prevenciji prijevremenog poroda kod ljudskog pacijenta, pri čemu se spoj primjenjuje kod pacijenta uz dodatno tokolitičko sredstvo.
2. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, da dodatno tokolitičko sredstvo je antagonist receptora oksitocina.
3. Spoj za uporabu prema patentnom zahtjevu 2, naznačen time, da antagonist receptora oksitocina je atosiban, retosiban, barusiban, epelsiban, ili nolasiban.
4. Spoj za uporabu prema patentnom zahtjevu 3, naznačen time, da antagonist receptora oksitocina je atosiban.
5. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, da dodatno tokolitičko sredstvo je inhibitor kalcijevog kanala.
6. Spoj za uporabu prema patentnom zahtjevu 5, naznačen time, da inhibitor kalcijevog kanala je nifedipin ili nikardipin.
7. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time, da se spoj i dodatno tokolitičko sredstvo primjenjuju kod pacijenta s betamimetikom, magnezijevom soli, donorom dušičnog oksida, progesteronom ili 17-α-hidroksiprogesteron kaproatom, ili kortikosteroidom.
8. Spoj za uporabu prema patentnom zahtjevu 7, naznačen time, da se spoj i dodatno tokolitičko sredstvo daju pacijentu s betamimetikom koji se bira iz skupine koju čine terbutalin, ritodrin, heksoprenalin, albuterol, fenoterol, nilidrin, i orciprenalin.
9. Spoj za uporabu prema patentnom zahtjevu 7, naznačen time, da se spoj i dodatno tokolitičko sredstvo daju pacijentu s magnezijevim sulfatom.
10. Spoj za uporabu prema patentnom zahtjevu 7, naznačen time, da se spoj i dodatno tokolitičko sredstvo daju pacijentu s nitroglicerinom.
11. Spoj za uporabu prema patentnom zahtjevu 7, naznačen time, da se spoj i dodatno tokolitičko sredstvo daju pacijentu s kortikosteroidom koji se bira iz skupine koju čine betametazon, deksametazon, i hidrokortizon.
12. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-11, naznačen time, da je spoj predstavljen formulom (III) [image]
13. Spoj za uporabu prema patentnom zahtjevu 12, naznačen time, da je spoj u kristaliničnom stanju.
14. Spoj za uporabu prema patentnom zahtjevu 13, naznačen time, da spoj pokazuje maksimume 1H nuklearne magnetske rezonance (NMR), koji su centrirani na 1,1 ppm, 3,3 ppm, 4,9 ppm, 5,4 ppm, 7,1 ppm, 7,7 ppm, 7,9 ppm, i 8,0 ppm.
15. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-14, naznačen time, da se spoj daje pacijentu oralno.
16. Spoj za uporabu prema patentnom zahtjevu 15, naznačen time, da se spoj formulira kao tableta, kapsula, gel kapsula, prašak, tekuća otopina, ili tekuća suspenzija.
17. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-16, dok je pacijent, naznačen time, da se radi o gestacijskoj dobi od 24 tjedna do 34 tjedna.
18. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-17, naznačen time, da se spoj nalazi unutar farmaceutskog pripravka koji nadalje sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
HRP20220674TT 2016-01-04 2017-01-04 Zajednička primjena alfa-amino estera derivata hidroksipropiltiazolidin karboksamida i tokolitičkog sredstva HRP20220674T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662274674P 2016-01-04 2016-01-04
US14/987,586 US9447055B1 (en) 2016-01-04 2016-01-04 α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US201662395664P 2016-09-16 2016-09-16
US201662407918P 2016-10-13 2016-10-13
EP17700391.0A EP3397622B1 (en) 2016-01-04 2017-01-04 Co-administration of alpha-amino ester of hydroxypropylthiazolidine carboxamide derivative and a tocolytic agent
PCT/EP2017/050099 WO2017118639A1 (en) 2016-01-04 2017-01-04 Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Publications (1)

Publication Number Publication Date
HRP20220674T1 true HRP20220674T1 (hr) 2022-07-22

Family

ID=57799697

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20220674TT HRP20220674T1 (hr) 2016-01-04 2017-01-04 Zajednička primjena alfa-amino estera derivata hidroksipropiltiazolidin karboksamida i tokolitičkog sredstva
HRP20220673TT HRP20220673T1 (hr) 2016-01-04 2017-01-04 L-valinat derivata hidroksipropiltiazolidin karboksamida, njegova sol i njegov kristalni oblik

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20220673TT HRP20220673T1 (hr) 2016-01-04 2017-01-04 L-valinat derivata hidroksipropiltiazolidin karboksamida, njegova sol i njegov kristalni oblik

Country Status (23)

Country Link
EP (4) EP4144351A1 (hr)
JP (5) JP6933322B2 (hr)
KR (2) KR20180099708A (hr)
CN (1) CN108779087A (hr)
AU (4) AU2017205670B2 (hr)
CA (2) CA3009573A1 (hr)
DK (2) DK3400217T3 (hr)
EA (1) EA036990B1 (hr)
ES (2) ES2916835T3 (hr)
HR (2) HRP20220674T1 (hr)
HU (2) HUE058871T2 (hr)
IL (4) IL284912B (hr)
LT (2) LT3397622T (hr)
MA (2) MA43580A (hr)
MX (3) MX2018008304A (hr)
PL (2) PL3400217T3 (hr)
PT (2) PT3397622T (hr)
RS (2) RS63286B1 (hr)
SG (4) SG11201804789QA (hr)
SI (2) SI3400217T1 (hr)
UA (2) UA125377C2 (hr)
WO (2) WO2017118641A1 (hr)
ZA (1) ZA201903769B (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL284912B (en) * 2016-01-04 2022-07-01 Merck Serono Sa L-Valinate derivative of hydroxypropylthiazolidine carboxamide and salt form, crystalline polymorph thereof
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
EP4034129A4 (en) * 2019-09-23 2023-11-01 The Board of Trustees of the Leland Stanford Junior University TREATMENT PROCEDURES FOR GESTATIONAL EXTENSION AND FOR MENSTRUAL OR GESTATIONAL COMPLICATIONS

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835175A (en) 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US3839396A (en) 1971-07-15 1974-10-01 Shionogi & Co 9-lower alkyl-9-fluorenyl carbonates
US4108846A (en) 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
US4508657A (en) 1982-01-19 1985-04-02 Research Corporation Peptide synthesis and amino acid blocking agents
US4581167A (en) 1982-01-19 1986-04-08 Research Corporation Peptide synthesis and amino acid blocking agents
EP0112809B1 (en) 1982-12-21 1986-05-28 Ferring AB Vasotocin derivatives
US4460501A (en) 1983-08-30 1984-07-17 Research Corporation Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
IN188411B (hr) * 1997-03-27 2002-09-21 Yuhan Corp
AU2001261161A1 (en) * 2000-05-30 2001-12-11 Ortho-Mcneil Pharmaceutical, Inc. Dihydropyridine compounds for inhibition of calcium-influx
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
ES2277640T3 (es) 2002-02-27 2007-07-16 Ferring Bv Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina.
UA78021C2 (en) * 2002-03-28 2007-02-15 Applied Research Systems Thiazolidine carboxamide derivatives as modulators of prostaglandine f receptors
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2015192878A1 (en) 2014-06-16 2015-12-23 Glaxosmithkline Intellectual Property Development Limited Retosiban for the treatment of pre-term labour
CN106795110A (zh) 2014-07-02 2017-05-31 奥布赛瓦股份公司 治疗ot‑r活性相关的病症的方法中可用的晶体(3z,5s)‑5‑(羟甲基)‑1‑[(2’‑甲基‑1,1’‑联苯‑4‑基)羰基]吡咯烷‑3‑酮o‑甲基肟
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
IL284912B (en) 2016-01-04 2022-07-01 Merck Serono Sa L-Valinate derivative of hydroxypropylthiazolidine carboxamide and salt form, crystalline polymorph thereof
US9447055B1 (en) * 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Also Published As

Publication number Publication date
EP3400217B1 (en) 2022-03-09
DK3400217T3 (da) 2022-06-07
PL3400217T3 (pl) 2022-07-04
HUE058872T2 (hu) 2022-09-28
AU2021218003A1 (en) 2021-09-02
IL260286B (en) 2022-02-01
ES2915948T3 (es) 2022-06-27
MX2018008157A (es) 2018-09-03
KR20180099708A (ko) 2018-09-05
JP2019501897A (ja) 2019-01-24
IL289256A (en) 2022-02-01
UA125118C2 (uk) 2022-01-12
JP2023002668A (ja) 2023-01-10
LT3397622T (lt) 2022-06-27
ZA201903769B (en) 2023-03-29
AU2021218009A1 (en) 2021-09-09
JP7432284B2 (ja) 2024-02-16
EA036990B1 (ru) 2021-01-25
CN108779087A (zh) 2018-11-09
WO2017118639A1 (en) 2017-07-13
WO2017118641A1 (en) 2017-07-13
AU2017205670A1 (en) 2018-08-16
JP2019500351A (ja) 2019-01-10
SG11201804594YA (en) 2018-06-28
JP2024012376A (ja) 2024-01-30
AU2023233151A1 (en) 2023-10-12
SG10202009723PA (en) 2020-11-27
KR20180100120A (ko) 2018-09-07
LT3400217T (lt) 2022-06-27
MA43549A (fr) 2021-05-26
JP6933322B2 (ja) 2021-09-08
MX2022000154A (es) 2022-02-21
MX2018008304A (es) 2019-01-24
EP4140988A1 (en) 2023-03-01
AU2017205670B2 (en) 2021-05-20
SG11201804789QA (en) 2018-07-30
PL3397622T3 (pl) 2022-07-04
AU2017205254A1 (en) 2018-08-16
JP7377588B2 (ja) 2023-11-10
UA125377C2 (uk) 2022-03-02
HRP20220673T1 (hr) 2022-07-08
IL259742B (en) 2021-08-31
PT3397622T (pt) 2022-06-15
IL284912B (en) 2022-07-01
AU2017205254B2 (en) 2021-05-20
HUE058871T2 (hu) 2022-09-28
CA3009576A1 (en) 2017-07-13
SI3397622T1 (sl) 2022-07-29
EP3397622B1 (en) 2022-03-09
EA201891095A1 (ru) 2019-01-31
SI3400217T1 (sl) 2022-07-29
JP7169573B2 (ja) 2022-11-11
IL259742A (en) 2018-07-31
PT3400217T (pt) 2022-06-15
DK3397622T3 (en) 2022-06-07
EP3400217A1 (en) 2018-11-14
AU2021218009B2 (en) 2023-06-22
JP2021178858A (ja) 2021-11-18
RS63285B1 (sr) 2022-06-30
ES2916835T3 (es) 2022-07-06
EP3397622A1 (en) 2018-11-07
CA3009573A1 (en) 2017-07-13
IL284912A (en) 2021-08-31
IL260286A (en) 2018-07-31
SG10202009769WA (en) 2020-11-27
EP4144351A1 (en) 2023-03-08
MA43580A (fr) 2021-05-26
RS63286B1 (sr) 2022-06-30

Similar Documents

Publication Publication Date Title
HK1250714A1 (zh) 雜芳基衍生物或其藥學上可接受的鹽、其製備方法以及包含其作為活性成分的用於預防或治療pi3激酶相關疾病的藥物組合物
JP2015078230A5 (hr)
HRP20220674T1 (hr) Zajednička primjena alfa-amino estera derivata hidroksipropiltiazolidin karboksamida i tokolitičkog sredstva
JP2014129360A5 (hr)
MX2015010971A (es) Derivado novedoso de pirazol.
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
JP2017517565A5 (hr)
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
PH12014502107B1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
EP3498280A4 (en) ADMINISTRATION AND DOSAGE OF A THERAPEUTIC AGENT FOR ENDOMETRIOSIS
MD4563C1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
EP3248603A4 (en) Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
WO2015093847A8 (en) Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same
IL281217A (en) Pharmaceutical preparation for controlled release of weak acid drugs and its uses
RU2014147728A (ru) Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
WO2016139681A3 (en) Pharmaceutical composition of tizanidine and process for preparing the same
HRP20230105T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti
NZ630795A (en) Crystalline form of vsn16